Adenosine A2A Receptor as a Potential Drug Target - Current Status and Future Perspectives

被引:27
作者
Al-Attraqchi, Omar H. A. [1 ]
Attimarad, Mahesh [2 ]
Venugopala, Katharigatta N. [2 ,3 ]
Nair, Anroop [2 ]
Al-Attraqchi, Noor H. A. [4 ]
机构
[1] Philadelphia Univ, Fac Pharm, POB 1, Amman 19392, Jordan
[2] King Faisal Univ, Coll Clin Pharm, Dept Pharmaceut Sci, Al Hasa 31982, Saudi Arabia
[3] Durban Univ Technol, Dept Biotechnol & Food Technol, ZA-4001 Durban, South Africa
[4] Univ Mosul, Dept Pharmacognosy, Mosul, Iraq
关键词
Adenosine A(2A) receptor; molecular modeling; myocardial perfusion imaging; Parkinson's disease; depression; cancer immunotherapy; PARKINSONS-DISEASE; MOLECULAR DOCKING; PHARMACOLOGICAL EVALUATION; PYRIMIDINE-DERIVATIVES; CANCER-IMMUNOTHERAPY; IMMUNE CHECKPOINTS; CRYSTAL-STRUCTURE; PARTIAL AGONISTS; BINDING MODE; HUMAN A(1);
D O I
10.2174/1381612825666190716113444
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Adenosine receptors (ARs) are a class of G-protein coupled receptors (GPCRs) that are activated by the endogenous substance adenosine. ARs are classified into 4 subtype receptors, namely, the A(1), A(2A), A(2B) and A(3) receptors. The wide distribution and expression of the ARs in various body tissues as well as the roles they have in controlling different functions in the body make them potential drug targets for the treatment of various pathological conditions, such as cardiac diseases, cancer, Parkinson's disease, inflammation and glaucoma. Therefore, in the past decades, there have been extensive investigations of ARs with a high number of agonists and antagonists identified that can interact with these receptors. This review shall discuss the A(2A) receptor (A(2A)AR) subtype of the ARs. The structure, properties and the recent advances in the therapeutic potential of the receptor are discussed with an overview of the recent advances in the methods of studying the receptor. Also, molecular modeling approaches utilized in the design of A(2A)AR ligands are highlighted with various recent examples.
引用
收藏
页码:2716 / 2740
页数:25
相关论文
共 172 条
  • [1] Recent Advances in the In-silico Structure-based and Ligand-based Approaches for the Design and Discovery of Agonists and Antagonists of A2A Adenosine Receptor
    Agrawal, Nikhil
    Chandrasekaran, Balakumar
    Al-Aboudi, Amal
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (07) : 774 - 782
  • [2] Ahmed A, 2018, INT SOC OPTICS PHOTO, DOI [10.1117/12.2281326, DOI 10.1117/12.2281326]
  • [3] QSAR AND PHARMACOPHORE MODELING OF 4-ARYLTHIENO [3, 2-d] PYRIMIDINE DERIVATIVES AGAINST ADENOSINE RECEPTOR OF PARKINSON'S DISEASE
    Ahmed, Shiek S. S. J.
    Ahameethunisa, A.
    Santosh, Winkins
    [J]. JOURNAL OF THEORETICAL & COMPUTATIONAL CHEMISTRY, 2010, 9 (06) : 975 - 991
  • [4] Molecular Basis of Modulating Adenosine Receptors Activities
    Al-Qattan, Mohammed Nooraldeen Mahmod
    Mordi, Mohd Nizam
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (07) : 817 - 831
  • [5] Molecular Dynamics Simulations of Adenosine Receptors: Advances, Applications and Trends
    Al-Shar'i, Nizar A.
    Al-Balas, Qosay A.
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (07) : 783 - 816
  • [6] Adenosine A2A receptors are up-regulated and control the activation of human alveolar macrophages
    Alfaro, Tiago M.
    Rodrigues, Diana I.
    Tome, Angelo R.
    Cunha, Rodrigo A.
    Cordeiro, Carlos Robalo
    [J]. PULMONARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 : 90 - 94
  • [7] Keloids: The paradigm of skin fibrosis - Pathomechanisms and treatment
    Andrews, Jonathan P.
    Marttala, Jaana
    Macarak, Edward
    Rosenbloom, Joel
    Uitto, Jouni
    [J]. MATRIX BIOLOGY, 2016, 51 : 37 - 46
  • [8] Structure-based drug design of chromone antagonists of the adenosine A2A receptor
    Andrews, Stephen P.
    Mason, Jonathan S.
    Hurrell, Edward
    Congreve, Miles
    [J]. MEDCHEMCOMM, 2014, 5 (05) : 571 - 575
  • [9] Binding mode similarity measures for ranking of docking poses: a case study on the adenosine A2A receptor
    Anighoro, Andrew
    Bajorath, Juergen
    [J]. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2016, 30 (06) : 447 - 456
  • [10] [Anonymous], APPL COMPUTERS PHARM